EQUEST PRAMOX VETERINARY

Valsts: Izraēla

Valoda: angļu

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

MOXIDECTIN; PRAZIQUANTEL

Pieejams no:

ZOETIS ISRAEL HOLDING B.V., ISRAEL

Zāļu forma:

GEL

Kompozīcija:

MOXIDECTIN 1.95 %W/W; PRAZIQUANTEL 12.17 %W/W

Ievadīšanas:

PER OS

Receptes veids:

Required

Ražojis:

ZOETIS MANUFACTURING & RESEARCH SPAIN, S.L

Ārstēšanas norādes:

Equest pramox veterinary is indicated for treatment of mixed cestodes and nematodes or arthropods infections in horses, caused by moxidectin and praziquantel sensitive strains of : Large strongyles, small strongyles (adults and intraluminal larval stages), ascarids and other species, tapeworm (adults). The egg reappearance period of small strongyles is 90 days. The product is effective against (developing) intramucosal L4 stages of small strongyles. At 8 weeks after treatment, early (hypobiotic) EL3 stages of small strongyles are eliminated.

Autorizācija datums:

2016-04-30

Lietošanas instrukcija

EQU GEL PL SH130222
VETERINARY MEDICINE PACKAGE LEAFLET
This medicine is dispensed with a veterinarian’s
prescription only
For use in animals only
1. NAME, FORM AND STRENGTH OF THE
VETERINARY MEDICINE:
Equest Pramox Veterinary Oral Gel )per os(
2. ACTIVE INGREDIENT
Moxidectin 1.95 %w/w
Praziquantel 12.17 %w/w
List of the inactive ingredients in section 13.
3. WHAT IS THIS MEDICINE INTENDED FOR?
For treatment of mixed cestodes and nematodes or
arthropods infections in horses, caused by:
moxidectin and praziquantel sensitive strains of large
strongyles, small strongyles )adults and intraluminal
larval stages(, ascarids and other species, and
tapeworm )adults(.
The egg reappearance period of small strongyles is
90 days.
The product is effective against developing intramucosal
L4 stages of small strongyles.
At 8 weeks after treatment, early )hypobiotic( EL3 stages
of small strongyles are eliminated.
4. CONTRAINDICATIONS
Do not administer to young foals less than 6.5 months
old.
Do not use in case of known hypersensitivity to the active
ingredients or to any of the inactive ingredients in the
medicine.
The medicine is intended for horses only. Dogs and
cats that come into contact with the gel or with a used
syringe may suffer from side effects due to the dosage
of moxidectin.
5. SIDE EFFECTS
Mouth pain, flaccid lower lip, swelling of the muzzle,
hypersalivation and anorexia have been observed in rare
cases. Lack of muscle control )ataxia( has been reported
on rare occasions and lethargy in very rare cases. These
effects are transient and disappear spontaneously. In
case of very high worm burdens, destruction of the
parasites may cause a mild stomachache )colic( and
diarrhoea in the treated animal. You can report side
effects to the Ministry of Health by following the link
‘Reporting Side Effects of Drug Treatment’ on the
Ministry home page )www.health.gov.il( which links to
an online form for reporting side effects. You can also
use this link: https://sideeffects.health.gov.il.
6. TARGET ANIMALS
Horses
7. METHOD

Produkta apraksts

Equest Pramox Veterinary LPD 14.10.2021
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Equest Pramox Veterinary
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES
Moxidectin
1.95 % w/w
Praziquantel
12.17 % w/w
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Oral Gel.
Pale yellow to orange/pink oral gel.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Equest pramox veterinary is indicated for treatment of mixed cestodes
and nematodes or
arthropods infections in horses, caused by moxidectin and praziquantel
sensitive strains
of: Large strongyles, small strongyles (adults and intraluminal larval
stages), ascarids and
other species, tapeworm (adults).
The egg reappearance period of small strongyles is 90 days.
The product is effective against (developing) intramucosal L4 stages
of small strongyles.
At 8 weeks after treatment, early (hypobiotic) EL3 stages of small
strongyles are
eliminated.
4.3
CONTRAINDICATIONS
Do not administer to young foals less than 6.5 months old
Do not use in case of hypersensitivity to the active substance or to
any of the excipients
The product has been formulated specifically for use in horses only.
Dogs and cats may be
adversely affected by the concentration of moxidectin in this product
if they are allowed to
ingest spilled gel or have access to used syringes.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices, because they
increase the risk of
development of resistance and could ultimately result in ineffective
therapy:
-
Too frequent and repeated use of anthelmintics from the same class,
over an
extended period of time;
-
Under-dosing which may due to underestimation of body weight,
misadministration of
the product, or lack of calibration of the dosing device (If any).
Equest Pramox Veterinary LPD 14.10.2021
-
Suspected clinical cases of resistance to anthelmintics should be
further investigated
using appropriate tests